Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 4/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MME | P08473 | 1/20 | 0.47 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.46 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3324393 | 0.86 | LTA4H (0.49) | RENNPC1RAB9AMMEPSMB5 | |
| SCHEMBL5709671 | 0.83 | PSEN1 (0.59) | REN | |
| SCHEMBL9282508 | 0.83 | PSEN1 (0.59) | REN | |
| SCHEMBL4687328 | 0.82 | NPC1 (0.50) | NPC1RAB9A | |
| SCHEMBL6193303 | 0.81 | NPC1 (0.56) | NPC1RAB9AMME | |
| SCHEMBL3627449 | 0.81 | NPC1 (0.56) | NPC1RAB9AMME | |
| SCHEMBL4687372 | 0.81 | NPC1 (0.56) | NPC1RAB9AMME | |
| SCHEMBL6192393 | 0.81 | NPC1 (0.56) | NPC1RAB9AMME | |
| SCHEMBL27418997 | 0.81 | NPC1 (0.56) | NPC1RAB9AMME | |
| SCHEMBL27798809 | 0.81 | NPC1 (0.56) | NPC1RAB9AMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6906104-B2 | Aminediols for the treatment of Alzheimer's disease | PHARMACIA & UPJOHN COMPANY (US) | 2005-06-14 | — | — | US | disclosed |
| US-20030092747-A1 | Aminediols for the treatment of Alzheimer's disease | PHARMACIA & UPJOHN COMPANY | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092747-A1 | Aminediols for the treatment of Alzheimer's disease | BACE1, APP, BACE2 | REN 2055/4885NPC1 703/4885RAB9A 3696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.